Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in The Netherlands

Journal of Pediatrics

Volumn 136, Issue 6, 2000, Pages 780-788

  Van Rossum, Annemarie M C ^a,b,c,d,e,f   Niesters, Hubert G M ^a,b,c,d,e,f   Geelen, Sibyl P M ^a,b,c,d,e,f   Scherpbier, Henriëtte J ^a,b,c,d,e,f   Hartwig, Nico G ^a,b,c,d,e,f   Weemaes, Corrie M R ^a,b,c,d,e,f   Veerman, Arjo J P ^a,b,c,d,e,f   Suur, Marja H ^a,b,c,d,e,f   De Graeff Meeder, Elizabeth R ^a,b,c,d,e,f   Slieker, Walentina A T ^a,b,c,d,e,f   Hop, Wim C J ^a,b,c,d,e,f   Osterhaus, Albert D M E ^a,b,c,d,e,f   Burger, David M ^a,b,c,d,e,f   De Groot, Ronald ^a,b,c,d,e,f  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d EMMA CHILDREN S HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CATCH UP GROWTH; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; NAUSEA; NETHERLANDS; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; VIRUS LOAD; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0034045783     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(00)94347-6     Document Type: Article

References (32)

1. 1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [see comments]. N Engl J Med 1997; 337:734-9.
2. 2. Horneff G, Adams O, Wahn V. Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children. AIDS 1998;12:489-94.
3. 3. Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996;97:886-90.
4. 4. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997;16:968-74.
5. 5. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997;336: 1704-12.
6. 6. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998;279:756-61.
7. 7. McKinney RE Jr, Maha MA, Connor EM, Feinberg J, Scott GB, Wulfsohn M, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med 1991;324:1018-25.
8. 8. Lewis LL, Venzon D, Church J, Farley M, Wheeler S, Keller A, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996;174:16-25.
9. 9. Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, McKinney RE Jr, et al. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. Pediatrics 1998;101:214-20.
10. 10. Kline M, Dunkle L, Church J, Goldsmith J, Harris A, Federici M, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995;96:247-52.
11. 11. Pizzo P, Eddy J, Falloon J, Balis F, Murphy R, Moss H, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-96.
12. 12. Butler K, Husson R, Balis F. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;324:137-44.
13. 13. Stein D, Drusano G, Steigbigel R, Berry P, Mellors J, McMahon D, et al. Two year follow-up of patients treated with indinavir 800 mg/8h. In: Fourth Conference of Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC; 1997.
14. 14. Mueller BU, Sleasman J, Nelson R, Smith S, Deutsch P, Ju W, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998;102:101-9.
15. 15. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.
16. 16. Wintergerst U, Hoffmann F, Solder B, Notheis G, Petropoulou T, Eberle J, et al. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1998;17: 495-9.
17. 17. Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddl) in children infected with the human immunodeficiency virus. J Pediatr 1998;132:543-6.
18. 18. Monpoux F, Sirvent N, Cottalorda J, Mariani R, Lefbvre JC. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience [letter]. AIDS 1997;11:1523-5.
19. 19. Mueller BU, Nelson RP Jr, Sleasman J, Zuckerman J, Heath-Chiozzi M, Steinberg SM, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998;101: 335-43.
20. 20. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997;11: F107-11.
21. 21. Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, et al. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998;177:625-33.
22. 22. McGann KA. Management of infants with HIV-1 infection. The report on pediatric infectious diseases. Pediatric Infectious Diseases Society of America; 1996;6:3-4.
23. 23. van Wieringen JC, Roede MJ, Wit JM. [Growth diagrams for patient care]. Tijdschr Kindergeneeskd 1985; 53:147-52.
24. 24. Strauss K, Kannet I, Engels S, Shiba A, Ward DM, Ullery S, et al. Performance evaluation of the FACSCount System: a dedicated system for clinical cellular analysis. Cytometry 1996;26:52-9.
25. 25. Sun R, Ku J, Jayakar H, Kuo J, Brambilla D, Herman S, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998;36:2964-9.
26. 26. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980. p. 58-9.
27. 27. Berhane R, Bagenda D, Marum L, Aceng E, Ndugwa C, Bosch RJ, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics 1997;100:E7.
28. 28. McKinney RE Jr, Wilfert C. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group. J Pediatr 1994;125:728-33.
29. 29. Tovo PA, de Martino M, Gabiano C, Cappello N, D'Elia R, Loy A, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet 1992;339:1249-53.
30. 30. Mofenson L, Moye L, Nugent R, Bethel J, Korelitz J. Relation of mortality risk to selected pediatric HIV disease progression endpoints (DPE) used in pediatric HIV therapeutic trials [abstract 1123]. In: Interscience Convention on Antimicrobial Agents and Chemotherapy; 1993 Oct 20 1993; New Orleans, La; 1993.
31. 31. Burger DM, Hoetelmans RMW, Mulder JW, Meenhorst PL, Hugen PWH, Brinkman K, et al. Low plasma levels of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy. Antiviral Ther 1998;3:215-20.
32. 32. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR Morb Mortal Wkly Rep 1994;43:1-19.